Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. (NYSE American: IGC) is a clinical-stage biotechnology company whose news flow centers on Alzheimer's disease drug development, pharmaceutical cannabinoids, and AI-enabled research. The company regularly reports updates on its lead asset, IGC-AD1, a cannabinoid-based therapy in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia, along with progress across its broader pipeline and AI platforms.
News about IGC Pharma often includes clinical trial milestones, such as enrollment progress and expansion of the CALMA study to new sites. For example, the company has highlighted reaching key enrollment thresholds and adding hybrid and virtual clinical sites like Dominion Medical Associates, part of Lightship's network, to improve access for patients in underserved and rural communities. These announcements provide insight into trial design, recruitment strategies, and geographic reach.
Investors and observers can also expect corporate and financial updates, including capital raises under an effective Form S-3 shelf registration statement, strategic divestitures of non-core assets, and changes to the company's fiscal year-end to align with the calendar year. SEC-reported events, such as registered direct offerings and asset sale closings, are frequently accompanied by press releases that explain how proceeds and transactions relate to IGC Pharma's clinical and research priorities.
Another recurring theme in IGC Pharma's news is AI and intellectual property developments. The company reports advances in its MINT-AD platform for Alzheimer's risk stratification and early detection, recognition from the National Institute on Aging for AI code quality, and new or allowed patents that expand its pharmaceutical cannabinoid portfolio, including microdose-based treatments for stuttering and Tourette's Syndrome.
In addition, IGC Pharma issues news on community and educational initiatives, such as sponsoring a caregiver-focused Alzheimer's book authored by neuropsychology experts. Together, these news items provide a view into the company's clinical progress, AI research, regulatory positioning, capital strategy, and engagement with the Alzheimer's community. Readers interested in IGC's stock and operations can use this news feed to follow trial updates, financing events, patent activity, and strategic decisions over time.
IGC Pharma (NYSE American:IGC) has achieved 50% enrollment in its Phase 2 CALMA clinical trial for IGC-AD1, a treatment targeting agitation in Alzheimer's disease. The trial is a multicenter, double-blind, placebo-controlled, randomized study evaluating their proprietary formulation that combines low-dose THC with another active pharmaceutical ingredient.
The company has expanded its trial network to include six new research sites across Florida, Ontario, Rhode Island, Oklahoma, British Columbia, and Puerto Rico. IGC-AD1 shows promise through its multi-modal mechanism of action, potentially addressing both agitation symptoms and disease modification. Based on encouraging Phase 1 data and interim Phase 2 analysis, the company expects to complete the trial in early 2026.
IGC Pharma (NYSE American:IGC), a clinical-stage pharmaceutical company, has received its third award from the National Institute on Aging (NIA) for excellence in AI code development as part of the PREPARE Challenge. The company's AI team was recognized for developing well-structured and transparent code for Alzheimer's detection.
The team created a multilingual AI model using DementiaBank data to detect acoustic biomarkers linked to early cognitive decline. The company's AI initiatives include MINT-AD, an advanced platform integrating multiple biomarkers for individualized Alzheimer's disease forecasting. Previously, IGC received the Disproportionate Impact Award, third place in Phase 1, and a prize for generalization in Phase 2 of the PREPARE Challenge.
IGC Pharma (NYSE American:IGC) announced the expansion of its Phase 2 CALMA clinical trial for IGC-AD1, a novel treatment for agitation in Alzheimer's dementia, to Island Health's Royal Jubilee Hospital in Victoria, British Columbia, Canada.
The CALMA trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of IGC-AD1 in managing agitation in Alzheimer's patients. This expansion strengthens the trial's clinical infrastructure across North America and aims to increase access for patients and caregivers while supporting timely enrollment towards trial completion.
IGC Pharma (NYSE American:IGC) has received a Notice of Allowance from the USPTO for patent application US 17/613,909 (IGC510), covering a novel treatment method using THC and/or CBD for stammering, stuttering, and Tourette's syndrome. The therapeutic approach combines microdoses of THC with atypical antipsychotics to target the endocannabinoid system.
The treatment aims to serve an estimated 75 million people globally affected by these conditions. The patent adds to IGC's portfolio, which includes treatments for Alzheimer's, pain, and eating disorders. The company plans to develop clinical formulations similar to their flagship medication IGC-AD1, currently in Phase 2 CALMA clinical trials.
IGC Pharma (NYSE American:IGC) announced that Ascendiant Capital Markets has released a new coverage report on the company. The report raises the price target to $4.50 and suggests that upcoming clinical data and progress in 2025 could serve as strong catalysts for the stock.
The company explicitly stated that analyst views represent their independent opinions and that IGC Pharma is not responsible for the content, accuracy, or timelines provided in such reports.
IGC Pharma (NYSE American:IGC) has expanded its Phase 2 clinical trial for IGC-AD1, a drug candidate targeting agitation in Alzheimer's disease patients, by adding a new site at the Lynn Health Science Institute (LHSI) in Oklahoma City.
The CALMA trial, designed as a randomized, double-blind, placebo-controlled study, will be led by Principal Investigator Dr. Carl Griffin at the new site. The trial aims to evaluate IGC-AD1's safety and efficacy in addressing one of Alzheimer's most challenging symptoms - agitation, which often leads to earlier institutionalization and increased caregiver stress.
IGC Pharma (NYSE American:IGC) reported Q1 fiscal 2026 financial results, highlighting progress in its Phase 2 CALMA trial for Alzheimer's disease treatment. Revenue increased 21% to $328,000 compared to Q1 FY2025. The company reduced its net loss to $1.6 million ($0.02 per share) from $2.3 million year-over-year.
Notable achievements include expansion of trial sites across North America for IGC-AD1, a cannabinoid-based treatment for Alzheimer's agitation, advancement of MINT-AD AI platform for early Alzheimer's detection, and extension of an undrawn $12 million credit facility with O-Bank. The company successfully reduced SG&A expenses by 28% to $1.2 million and raised $3.5 million through private placements and ATM offering.
IGC Pharma (NYSE:IGC) announced promising preclinical results for two Alzheimer's disease treatments. Their lead candidate IGC-M3, a novel small molecule, demonstrated significant activity against multiple Alzheimer's pathology drivers, including over 90% prevention of beta-amyloid fibril formation and superior antioxidant performance compared to vitamin C.
The company is pursuing a dual-strategy approach with IGC-AD1, a cannabinoid-based therapy currently in Phase 2 clinical trials for Alzheimer's-related agitation, and IGC-M3, targeting multiple disease mechanisms in preclinical development. IGC-AD1 utilizes THC to address agitation affecting up to 76% of Alzheimer's patients, while IGC-M3 shows promise in disease modification through multiple pathways including amyloid reduction, metal ion regulation, and inflammation control.
IGC Pharma (NYSE American:IGC) has announced promising preclinical data for its investigational molecule IGC-M3 in the treatment of Alzheimer's disease. The in vitro studies demonstrate that IGC-M3 targets multiple biological mechanisms central to Alzheimer's pathology through four key actions:
The compound has shown ability to inhibit amyloid aggregation, promote disassembly of amyloid aggregates, neutralize reactive oxygen species, and reduce pro-inflammatory signaling in cellular models. In SH-SY5Y human neuronal cells, IGC-M3 demonstrated neuroprotective effects, while in BV2 microglial cells, it reduced Aβ42-induced activation and decreased pro-inflammatory markers.
The company plans to advance IGC-M3 to in vivo studies to evaluate its potential efficacy and safety in animal models, aiming to develop a disease-modifying treatment for Alzheimer's.
IGC Pharma (NYSE American: IGC) announced it will present three scientific posters at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31, 2025. The presentations will showcase the company's AI-driven innovations in Alzheimer's disease research.
The posters will highlight: 1) MINT-AD, an AI foundation model trained on 100+ global datasets for Alzheimer's risk assessment, 2) Research on using large language models to predict cognitive scores without brain scans or blood biomarkers, and 3) An AI-powered drug discovery pipeline focusing on GLP-1 and CB1 targets for Alzheimer's treatment.